GlassScriptPhysician profile
Kavitha Paramanathan
NPI 1700021847
$4,073.66
in general payments reported to CMS, 2019-2025
48 companies · $715 in 2025
The $715 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,930 · 2020: $409 · 2021: $20.00 · 2023: $297 · 2024: $704 · 2025: $715.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,715.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,715.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $661.24 | 2019-2025 | |
| Janssen Biotech, INC. | $273.80 | 2019-2025 | Tecvayli, Darzalex, Akeega |
| Celgene Corporation | $262.12 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Merck Sharp & Dohme LLC | $241.37 | 2019-2025 | Keytruda, Keytruda Qlex |
| Incyte Corporation | $229.47 | 2019-2024 | Jakafi, Monjuvi, Pemazyre |
| E.R. Squibb & Sons, L.L.C. | $218.72 | 2019-2025 | Opdivo, Opdualag |
| Pfizer INC. | $190.73 | 2019-2024 | |
| Genzyme Corporation | $183.36 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $159.15 | 2019-2025 | Lynparza |
| Amgen INC. | $147.35 | 2019-2020 | |
| Abbvie INC. | $109.93 | 2019-2025 | |
| Genentech USA, INC. | $99.72 | 2019-2024 | Columvi, Lunsumio, Polivy |
| Daiichi Sankyo INC. | $93.57 | 2019-2025 | Injectafer, Datroway |
| Eisai INC. | $76.86 | 2019-2024 | |
| Lilly USA, LLC | $75.01 | 2019-2023 | Verzenio, Jaypirca, Retevmo |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kavitha Paramanathan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.